MX2022007488A - Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6. - Google Patents
Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6.Info
- Publication number
- MX2022007488A MX2022007488A MX2022007488A MX2022007488A MX2022007488A MX 2022007488 A MX2022007488 A MX 2022007488A MX 2022007488 A MX2022007488 A MX 2022007488A MX 2022007488 A MX2022007488 A MX 2022007488A MX 2022007488 A MX2022007488 A MX 2022007488A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- alkyl
- cycloalkyl
- hydrogen
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
La descripción expone inhibidores selectivos y potentes de CDK 4/6 que muestran una inhibición ventajosa del crecimiento del cáncer, incluso a bajas concentraciones. Una clase de los inhibidores de CDK 4/6 se refiere a compuestos de pirrolopirimidinas sustituidas que tienen una porción de ácido graso y son específicamente derivados de Palbociclib de la fórmula general [2A], en donde R1 es hidrógeno, arilo, alquilo, alcoxi, cicloalquilo o heterociclilo; R2 es hidrógeno, halógeno, alquilo, acilo, cicloalquilo, alcoxi, alcoxialquilo, haloalquilo, hidroxialquilo, alquenilo, alquinilo, nitrilo o nitro; R3 es hidrógeno, halógeno, alquilo, haloalquilo, hidroxialquilo o cicloalquilo; y n es un número entero de 9 a 20. Estos compuestos pueden usarse como compuestos farmacéuticos para terapias anticancerígenas y son útiles para el tratamiento, la prevención y/o el mejoramiento del cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962948498P | 2019-12-16 | 2019-12-16 | |
| US202062966834P | 2020-01-28 | 2020-01-28 | |
| PCT/IB2020/061968 WO2021124104A1 (en) | 2019-12-16 | 2020-12-15 | Selective cdk4/6 inhibitor cancer therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007488A true MX2022007488A (es) | 2022-08-02 |
Family
ID=76807265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007488A MX2022007488A (es) | 2019-12-16 | 2020-12-15 | Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230044749A1 (es) |
| EP (1) | EP4077325A4 (es) |
| JP (1) | JP2023507141A (es) |
| KR (1) | KR20220113986A (es) |
| CN (1) | CN115023424A (es) |
| AU (1) | AU2020406362A1 (es) |
| BR (1) | BR112022011851A2 (es) |
| CA (1) | CA3164619A1 (es) |
| CR (1) | CR20220342A (es) |
| IL (1) | IL293932A (es) |
| MX (1) | MX2022007488A (es) |
| WO (1) | WO2021124104A1 (es) |
| ZA (1) | ZA202207448B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4376837A1 (en) * | 2021-07-28 | 2024-06-05 | Immunyx Pharma Ltd. | Compounds for neutrophil ros inhibition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030017357A1 (en) | 2001-07-13 | 2003-01-23 | Gould Electronics Inc. | Component of printed circuit boards |
| CN102295643B (zh) * | 2002-01-22 | 2013-12-04 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
| CN104447743B (zh) * | 2014-11-26 | 2016-03-02 | 苏州明锐医药科技有限公司 | 帕博西尼的制备方法 |
| BR112017021283A2 (pt) | 2015-04-16 | 2018-06-26 | Novartis Ag | comprimido de ribociclib |
| EP3636283A1 (en) | 2015-06-04 | 2020-04-15 | Pfizer Inc | Solid dosage forms of palbociclib |
| JP6951767B2 (ja) * | 2015-12-13 | 2021-10-20 | ハンジョウ イノゲート ファーマ カンパニー リミテッドＨａｎｇｚｈｏｕ Ｉｎｎｏｇａｔｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 抗癌薬として使用される複素環式化合物 |
| US11541051B2 (en) * | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| WO2019196812A1 (zh) * | 2018-04-09 | 2019-10-17 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
-
2020
- 2020-12-15 MX MX2022007488A patent/MX2022007488A/es unknown
- 2020-12-15 CN CN202080090850.9A patent/CN115023424A/zh active Pending
- 2020-12-15 US US17/785,239 patent/US20230044749A1/en active Pending
- 2020-12-15 JP JP2022537045A patent/JP2023507141A/ja active Pending
- 2020-12-15 IL IL293932A patent/IL293932A/en unknown
- 2020-12-15 KR KR1020227022840A patent/KR20220113986A/ko unknown
- 2020-12-15 EP EP20902114.6A patent/EP4077325A4/en active Pending
- 2020-12-15 CR CR20220342A patent/CR20220342A/es unknown
- 2020-12-15 CA CA3164619A patent/CA3164619A1/en active Pending
- 2020-12-15 WO PCT/IB2020/061968 patent/WO2021124104A1/en unknown
- 2020-12-15 AU AU2020406362A patent/AU2020406362A1/en active Pending
- 2020-12-15 BR BR112022011851A patent/BR112022011851A2/pt unknown
-
2022
- 2022-07-05 ZA ZA2022/07448A patent/ZA202207448B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220342A (es) | 2023-01-23 |
| IL293932A (en) | 2022-08-01 |
| ZA202207448B (en) | 2023-12-20 |
| CA3164619A1 (en) | 2021-06-24 |
| KR20220113986A (ko) | 2022-08-17 |
| CN115023424A (zh) | 2022-09-06 |
| JP2023507141A (ja) | 2023-02-21 |
| EP4077325A1 (en) | 2022-10-26 |
| AU2020406362A1 (en) | 2022-07-07 |
| US20230044749A1 (en) | 2023-02-09 |
| BR112022011851A2 (pt) | 2022-09-06 |
| EP4077325A4 (en) | 2023-11-15 |
| WO2021124104A1 (en) | 2021-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44721A (fr) | Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer | |
| EA201001618A1 (ru) | Ингибиторы syk протеинкиназ | |
| EA201990904A1 (ru) | 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы | |
| MD4582C1 (ro) | Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| MX2015008971A (es) | Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor. | |
| WO2013038429A3 (en) | Novel sglt inhibitors | |
| BR112018011788A2 (pt) | formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação | |
| MX2015010354A (es) | Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih). | |
| MX2011009146A (es) | Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh. | |
| MX348860B (es) | Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa. | |
| MX2016016538A (es) | Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa. | |
| BRPI0809542A8 (pt) | Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos | |
| CR20200418A (es) | Inhibidores de orginasa y sus mètodos de uso antecedentes | |
| MX2019006843A (es) | Inhibidor de cdk4/6. | |
| PH12018500294A1 (en) | 5-(n-benzyl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
| WO2012172566A3 (en) | Novel sglt inhibitors | |
| PH12018502012A1 (en) | Griseofulvin compound | |
| EA201270816A1 (ru) | Производные бензамида и их применение в качестве ингибиторов hsp90 | |
| BR112016023299A8 (pt) | composto tricíclico e inibidor de jak, agente preventivo, terapêutico ou de melhoria para doenças contra as quais inibição de jak é eficaz e para artrite reumatoide, medicamento e utilização desses compostos | |
| MX2022007488A (es) | Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6. | |
| ECSP22026478A (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
| MX2022015567A (es) | Productos terapeuticos contra el cancer de inhibidores selectivos de cdk4/6. | |
| ZA202207449B (en) | Selective cdk4/6 inhibitor cancer therapeutics | |
| BR112018000925A2 (pt) | composto heterocíclico contendo nitrogênio |